Kynurenine aminotransferases and the prospects of inhibitors for the treatment of schizophrenia

Current Medicinal Chemistry

Volumn 22, Issue 24, 2015, Pages 2902-2918

  Jayawickrama, Gayan S ^a   Sadig, Richard R ^a   Sun, Guanchen ^a   Nematollahi, Alireza ^a   Nadvi, Naveed A ^a   Hanrahan, Jane R ^a   Gorrell, Mark D ^b   Church, W Bret ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

BFF 122; BFF 816; Kat; Kat inhibitor; Kynurenic acid; Kynurenine; Kynurenine aminotransferase; PF 04859989; Phenylhydrazone; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 9 (4 AMINOPIPERAZIN 1 YL) 8 FLUORO 3 METHYL 6 OXO 2,3 DIHYDRO 6H 1 OXA 3A AZAPHENALENE 5 CARBOXYLIC ACID; AMINOTRANSFERASE INHIBITOR; BFF 816; DOPAMINE; HYDROXAMIC ACID DERIVATIVE; INDOLE DERIVATIVE; KYNURENIC ACID DERIVATIVE; KYNURENINE AMINOTRANSFERASE; KYNURENINE AMINOTRANSFERASE 1; KYNURENINE AMINOTRANSFERASE 2; KYNURENINE AMINOTRANSFERASE 3; KYNURENINE AMINOTRANSFERASE 4; KYNURENINE AMINOTRANSFERASE I INHIBITOR; KYNURENINE AMINOTRANSFERASE II INHIBITOR; KYNURENINE AMINOTRANSFERASE III INHIBITOR; KYNURENINE AMINOTRANSFERASE INHIBITOR; KYNURENINE AMINOTRANSFERASE IV INHIBITOR; NEUROLEPTIC AGENT; PHENYLHYDRAZONE DERIVATIVE; PYRAZOLE DERIVATIVE; S ESBA; UNCLASSIFIED DRUG; AMINOTRANSFERASE; KYNURENINE-OXOGLUTARATE TRANSAMINASE;

CENTRAL NERVOUS SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; GABAERGIC SYSTEM; GLUTAMATERGIC SYSTEM; HUMAN; HYPOTHESIS; NONHUMAN; PHARMACOPHORE; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM;

ANIMALS; HUMANS; SCHIZOPHRENIA; TRANSAMINASES;

EID: 84940877394     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150608094054     Document Type: Review

References (90)

1. Akladios, F. N.; Nadvi, N. A.; Park, J.; Hanrahan, J. R.; Kapoor, V.; Gorrell, M. D.; Church, W. B. Design and synthesis of novel inhibitors of human kynurenine aminotransferase-I. Bioorg. Med. Chem. Lett., 2012, 22, 1579-1581.
2. Erhardt, S.; Schwieler, L.; Nilsson, L.; Linderholm, K.; Engberg, G. The kynurenic acid hypothesis of schizophrenia. Physiol. Behav., 2007, 92, 203-209.
3. Andreasen, N. C. Symptoms, signs, and diagnosis of schizophrenia. Lancet, 1995, 346, 477-481.
4. Rossler, W.; Salize, H. J.; van Os, J.; Riecher-Rossler, A. Size of burden of schizophrenia and psychotic disorders. Eur. Neuropsychopharmacol., 2005, 15, 399-409.
5. Marwaha, S.; Johnson, S.; Bebbington, P.; Stafford, M.; Angermeyer, M. C.; Brugha, T.; Azorin, J. M.; Kilian, R.; Hansen, K.; Toumi, M. Rates and correlates of employment in people with schizophrenia in the UK, France and Germany. Br. J. Psychiatry, 2007, 191, 30-37.
6. Laursen, T. M.; Munk-Olsen, T.; Vestergaard, M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr. Opin. Psychiatry, 2012, 25, 83-88.
7. Meltzer, H. Y. Treatment of suicidality in schizophrenia. Ann. N. Y. Acad. Sci., 2001, 932, 44-58, discussion 58-60.
8. Carr, V. J.; Neil, A. L.; Halpin, S. A.; Holmes, S.; Lewin, T. J. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Aust N Z J. Psychiatry, 2003, 37, 31-40.
9. Wu, E. Q.; Birnbaum, H. G.; Shi, L.; Ball, D. E.; Kessler, R. C.; Moulis, M.; Aggarwal, J. The economic burden of schizophrenia in the United States in 2002. J. Clin. Psychiatry 2005, 66, 1122-1129.
10. Valenstein, M.; Blow, F. C.; Copeland, L. A.; McCarthy, J. F.; Zeber, J. E.; Gillon, L.; Bingham, C. R.; Stavenger, T. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr. Bull., 2004, 30, 255-564.
11. Bottlender, R.; Wegner, U.; Wittmann, J.; Strauss, A.; Moller, H. J. Deficit syndromes in schizophrenic patients 15 years after their first hospitalisation: Preliminary results of a follow-up study. Eur. Arch. Psychiatry Clin. Neurosci., 1999, 249(Suppl 4), 27-36.
12. Mueser, K. T.; Douglas, M. S.; Bellack, A. S.; Morrison, R. L. Assessment of enduring deficit and negative symptom subtypes in schizophrenia. Schizophr. Bull., 1991, 17, 565-582.
13. Erhardt, S.; Olsson, S. K.; Engberg, G. Pharmacological manipulation of kynurenic acid: Potential in the treatment of psychiatric disorders. CNS Drugs, 2009, 23, 91-101.
14. Stone, T. W.; Stoy, N.; Darlington, L. G. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol. Sci., 2013, 34, 136-143.
15. Hess, E. J.; Bracha, H. S.; Kleinman, J. E.; Creese, I. Dopamine receptor subtype imbalance in schizophrenia. Life Sci., 1987, 40, 1487-1497.
16. Laruelle, M.; Jaskiw, G. E.; Lipska, B. K.; Kolachana, B.; Casanova, M. F.; Kleinman, J. E.; Weinberger, D. R. D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment. Brain Res., 1992, 575, 47-56.
17. Akbarian, S. K. J., Potkin, S. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry, 1995, 52, 258- 266.
18. Huang, H.-S.; Akbarian, S. GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PLoS ONE, 2007, 2, e809.
19. Volk, D.; Austin, M.; Pierri, J.; Sampson, A.; Lewis, D. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am. J. Psychiatry 2001, 158, 256-265.
20. Hashimoto, T.; Volk, D. W.; Eggan, S. M.; Mirnics, K.; Pierri, J. N.; Sun, Z.; Sampson, A. R.; Lewis, D. A. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J. Neurosci., 2003, 23, 6315-6326.
21. Woo, T.-U.; Whitehead, R. E.; Melchitzky, D. S.; Lewis, D. A. A subclass of prefrontal γ-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc. Natl. Acad. Sci. USA, 1998, 95, 5341-5346.
22. Lewis, D. A.; Volk, D. W.; Hashimoto, T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: A novel target for the treatment of working memory dysfunction. Psychopharmacology, 2004, 174, 143-150.
23. Javitt, D. C.; Zukin, S. R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry, 1991, 148, 1301-1308.
24. Krystal, J. H.; Karper, L. P.; Seibyl, J. P.; Freeman, G. K.; Delaney, R.; Bremner, J. D.; Heninger, G. R.; Bowers, M. B. Jr.; Charney, D. S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry, 1994, 51, 199-214.
25. Jentsch, J. D.; Roth, R. H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 1999, 20, 201-225.
26. Kegeles, L. S.; Abi-Dargham, A.; Zea-Ponce, Y.; Rodenhiser-Hill, J.; Mann, J. J.; Van Heertum, R. L.; Cooper, T. B.; Carlsson, A.; Laruelle, M. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol. Psychiatry, 2000, 48, 627-640.
27. Paulson, L.; Martin, P.; Persson, A.; Nilsson, C. L.; Ljung, E.; Westman-Brinkmalm, A.; Eriksson, P. S.; Blennow, K.; Davidsson, P. Comparative genome- And proteome analysis of cerebral cortex from MK-801-treated rats. J. Neurosci. Res., 2003, 71, 526-533.
28. Woo, T. U.; Walsh, J. P.; Benes, F. M. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry, 2004, 61, 649-657.
29. Stone, T. W. Kynurenic acid antagonists and kynurenine pathway inhibitors. Expert Opin. Investig. Drugs, 2001, 10, 633-645.
30. Alkondon, M.; Pereira, E. F.; Yu, P.; Arruda, E. Z.; Almeida, L. E.; Guidetti, P.; Fawcett, W. P.; Sapko, M. T.; Randall, W. R.; Schwarcz, R.; Tagle, D. A.; Albuquerque, E. X. Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic receptors in the hippocampus. J. Neurosci., 2004, 24, 4635-4648.
31. Stone, T. W.; Darlington, L. G. The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Br. J. Pharmacol., 2013, 169(6), 1211-27.
32. Erhardt, S.; Blennow, K.; Nordin, C.; Skogh, E.; Lindstrom, L. H.; Engberg, G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett., 2001, 313, 96- 98.
33. Schwarcz, R.; Rassoulpour, A.; Wu, H.-Q.; Medoff, D.; Tamminga, C. A.; Roberts, R. C. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry, 2001, 50, 521-530.
34. Stone, T. W.; Darlington, L. G. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov., 2002, 1, 609-620.
35. Fukui, S.; Schwarcz, R.; Rapoport, S. I.; Takada, Y.; Smith, Q. R. Blood-brain barrier transport of kynurenines: Implications for brain synthesis and metabolism. J. Neurochem., 1991, 56, 2007-2017.
36. Han, Q.; Cai, T.; Tagle, D. A.; Li, J. Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell Mol. Life Sci., 2010, 67, 353-368.
37. Guidetti, P.; Amori, L.; Sapko, M. T.; Okuno, E.; Schwarcz, R. Mitochondrial aspartate aminotransferase: A third kynurenateproducing enzyme in the mammalian brain. J. Neurochem., 2007, 102, 103-111.
38. Bellocchi, D.; Macchiarulo, A.; Carotti, A.; Pellicciari, R. Quantum mechanics/molecular mechanics (QM/MM) modeling of the irreversible transamination of L-kynurenine to kynurenic acid: The round dance of kynurenine aminotransferase II. Biochem. Biophysics Acta, 2009, 1794, 1802-12.
39. Danysz, W.; Fadda, E.; Wroblewski, J. T.; Costa, E. Kynurenate and 2-amino-5-phosphonovalerate interact with multiple binding sites of the N-methyl-D-aspartate-sensitive glutamate receptor domain. Neurosci. Lett., 1989, 96, 340-344.
40. Moroni, F.; Cozzi, A.; Sili, M.; Mannaioni, G. Kynurenic acid: A metabolite with multiple actions and multiple targets in brain and periphery. J. Neural. Transm., 2012, 119, 133-139.
41. Moroni, F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur. J. Pharmacol., 1999, 375, 87-100.
42. Akahane, K.; Kato, M.; Takayama, S. Involvement of inhibitory and excitatory neurotransmitters in levofloxacin- And ciprofloxacininduced convulsions in mice. Antimicrob. Agents Chemother., 1993, 37, 1764-1770.
43. Carpenedo, R.; Chiarugi, A.; Russi, P.; Lombardi, G.; Carla, V.; Pellicciari, R.; Mattoli, L.; Moroni, F. Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities. Neuroscience, 1994, 61, 237-243.
44. Passera, E.; Campanini, B.; Rossi, F.; Casazza, V.; Rizzi, M.; Pellicciari, R.; Mozzarelli, A. Human kynurenine aminotransferase II-reactivity with substrates and inhibitors. FEBS J., 2011, 278, 1882-1900.
45. Han, Q.; Li, J. pH dependence, substrate specificity and inhibition of human kynurenine aminotransferase I. Eur. J. Biochem. 2004, 271, 4804-4814.
46. Cooper, A. J. L.; Pinto, J. T.; Krasnikov, B. F.; Niatsetskaya, Z. V.; Han, Q.; Li, J.; Vauzour, D.; Spencer, J. P. E. Substrate specificity of human glutamine transaminase K as an aminotransferase and as a cysteine S-conjugate β-lyase. Arch. Biochem. Biophysics., 2008, 474, 72-81.
47. Rossi, F.; Schwarcz, R.; Rizzi, M. Curiosity to kill the KAT (kynurenine aminotransferase): structural insights into brain kynurenic acid synthesis. Curr. Opin. Struct. Biol., 2008, 18, 748- 755.
48. Han, Q.; Robinson, H.; Cai, T.; Tagle, D. A.; Li, J. Structural insight into the inhibition of human kynurenine aminotransferase I/glutamine transaminase K. J. Med. Chem., 2009, 52, 2786-2793.
49. Han, Q.; Cai, T.; Tagle, D. A.; Robinson, H.; Li, J. Substrate specificity and structure of human aminoadipate aminotransferase/kynurenine aminotransferase II. Biosci. Rep., 2008, 28, 205-215.
50. Guidetti, P.; Okuno, E.; Schwarcz, R. Characterization of rat brain kynurenine aminotransferases I and II. J. Neurosci. Res., 1997, 50, 457-465.
51. Yu, P.; Li, Z.; Zhang, L.; Tagle, D. A.; Cai, T. Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family. Gene, 2006, 365, 111- 118.
52. Han, Q.; Robinson, H.; Cai, T.; Tagle, D. A.; Li, J. Biochemical and structural properties of mouse kynurenine aminotransferase III. Mol. Cell Biol., 2009, 29, 784-793.
53. Han, Q.; Cai, T.; Tagle, D. A.; Li, J. Thermal stability, pH dependence and inhibition of four murine kynurenine aminotransferases. BMC Biochem., 2010, 11, 1471-2091.
54. Jansonius, J. N. Structure, evolution and action of vitamin B6- dependent enzymes. Curr. Opin. Struct. Biol., 1998, 8, 759-769.
55. Rossi, F.; Han, Q.; Li, J.; Li, J.; Rizzi, M. Crystal structure of human kynurenine aminotransferase I. J. Biol. Chem., 2004, 279, 50214-50220.
56. Han, Q.; Robinson, H.; Cai, T.; Tagle, D. A.; Li, J. Biochemical and structural characterization of mouse mitochondrial aspartate aminotransferase, a newly identified kynurenine aminotransferase- IV. Biosci. Rep., 2011, 31, 323-332.
57. Potter, M. C.; Elmer, G. I.; Bergeron, R.; Albuquerque, E. X.; Guidetti, P.; Wu, H. Q.; Schwarcz, R. Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology, 2010, 35, 1734-1742.
58. Pocivavsek, A.; Wu, H. Q.; Potter, M. C.; Elmer, G. I.; Pellicciari, R.; Schwarcz, R. Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology, 2011, 36, 2357-2367.
59. Kozak, R.; Campbell, B. M.; Strick, C. A.; Horner, W.; Hoffmann, W. E.; Kiss, T.; Chapin, D. S.; McGinnis, D.; Abbott, A. L.; Roberts, B. M.; Fonseca, K.; Guanowsky, V.; Young, D. A.; Seymour, P. A.; Dounay, A.; Hajos, M.; Williams, G. V.; Castner, S. A. Reduction of brain kynurenic Acid improves cognitive function. J. Neurosci., 2014, 34, 10592-10602.
60. Wu, H. Q.; Okuyama, M.; Kajii, Y.; Pocivavsek, A.; Bruno, J. P.; Schwarcz, R. Targeting kynurenine aminotransferase II in psychiatric diseases: Promising effects of an orally active enzyme inhibitor. Schizophr. Bull., 2014, 40(Suppl 2), S152-S158.
61. Chess, A. C.; Simoni, M. K.; Alling, T. E.; Bucci, D. J. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr. Bull., 2007, 33, 797-804.
62. Shepard, P. D.; Joy, B.; Clerkin, L.; Schwarcz, R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology, 2003, 28, 1454-1462.
63. Erhardt, S.; Schwieler, L.; Emanuelsson, C.; Geyer, M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol. Psychiatry, 2004, 56, 255-260.
64. Pocivavsek, A.; Wu, H. Q.; Elmer, G. I.; Bruno, J. P.; Schwarcz, R. Pre- And postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur. J. Neurosci., 2012, 35, 1605-1612.
65. Akagbosu, C. O.; Evans, G. C.; Gulick, D.; Suckow, R. F.; Bucci, D. J. Exposure to kynurenic acid during adolescence produces memory deficits in adulthood. Schizophr. Bull., 2012, 38, 769-778.
66. Trecartin, K. V.; Bucci, D. J. Administration of kynurenine during adolescence, but not during adulthood, impairs social behavior in rats. Schizophr. Res., 2011, 133, 156-158.
67. DiNatale, B. C.; Murray, I. A.; Schroeder, J. C.; Flaveny, C. A.; Lahoti, T. S.; Laurenzana, E. M.; Omiecinski, C. J.; Perdew, G. H. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol. Sci., 2010, 115, 89-97.
68. Jones, A. L.; Mowry, B. J.; Pender, M. P.; Greer, J. M. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis? Immunol. Cell Biol., 2005, 83, 9-17.
69. Chiarugi, A.; Carpenedo, R.; Molina, M. T.; Mattoli, L.; Pellicciari, R.; Moroni, F. Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J. Neurochem., 1995, 65, 1176-1183.
70. Zwilling, D.; Huang, S. Y.; Sathyasaikumar, K. V.; Notarangelo, F. M.; Guidetti, P.; Wu, H. Q.; Lee, J.; Truong, J.; Andrews-Zwilling, Y.; Hsieh, E. W.; Louie, J. Y.; Wu, T.; Scearce-Levie, K.; Patrick, C.; Adame, A.; Giorgini, F.; Moussaoui, S.; Laue, G.; Rassoulpour, A.; Flik, G.; Huang, Y.; Muchowski, J. M.; Masliah, E.; Schwarcz, R.; Muchowski, P. J. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell, 2011, 145, 863-874.
71. Okuda, S.; Nishiyama, N.; Saito, H.; Katsuki, H. 3- Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J. Neurochem., 1998, 70, 299-307.
72. Lapin, I. P. Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice. J. Neural. Transm., 1978, 42, 37-43.
73. Sapko, M. T.; Guidetti, P.; Yu, P.; Tagle, D. A.; Pellicciari, R.; Schwarcz, R. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease. Exp. Neurol., 2006, 197, 31-40.
74. Amori, L.; Wu, H. Q.; Marinozzi, M.; Pellicciari, R.; Guidetti, P.; Schwarcz, R. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience, 2009, 159, 196-203.
75. Amori, L.; Guidetti, P.; Pellicciari, R.; Kajii, Y.; Schwarcz, R. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J. Neurochem., 2009, 109, 316- 325.
76. Myint, A. M.; Schwarz, M. J.; Verkerk, R.; Mueller, H. H.; Zach, J.; Scharpe, S.; Steinbusch, H. W.; Leonard, B. E.; Kim, Y. K. Reversal of imbalance between kynurenic acid and 3- hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav. Immun., 2011, 25, 1576-1581.
77. Johansson, A. S.; Owe-Larsson, B.; Asp, L.; Kocki, T.; Adler, M.; Hetta, J.; Gardner, R.; Lundkvist, G. B.; Urbanska, E. M.; Karlsson, H. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine. J. Psychiatr. Res., 2013, 47, 1815-1823.
78. Yao, J. K.; Dougherty, G. G. Jr.; Reddy, R. D.; Keshavan, M. S.; Montrose, D. M.; Matson, W. R.; Rozen, S.; Krishnan, R. R.; McEvoy, J.; Kaddurah-Daouk, R. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol. Psychiatry, 2010, 15, 938-953.
79. Kapoor, R.; Lim, K. S. Y.; Cheng, A.; Garrick, T.; Kapoor, V. Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT- 1). Brain Res., 2006, 1106, 205-210.
80. Wonodi, I.; Stine, O. C.; Sathyasaikumar, K. V.; Roberts, R. C.; Mitchell, B. D.; Hong, L. E.; Kajii, Y.; Thaker, G. K.; Schwarcz, R. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch. Gen. Psychiatry, 2011, 68, 665-674.
81. Pellicciari, R.; Rizzo, R. C.; Costantino, G.; Marinozzi, M.; Amori, L.; Guidetti, P.; Wu, H. Q.; Schwarcz, R. Modulators of the kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of (S)-4- (ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor. Chem. Med. Chem., 2006, 1, 528-531.
82. Pellicciari, R.; Venturoni, F.; Bellocchi, D.; Carotti, A.; Marinozzi, M.; Macchiarulo, A.; Amori, L.; Schwarcz, R. Sequence variants in kynurenine aminotransferase II (KAT II) orthologs determine different potencies of the inhibitor S-ESBA. Chem. Med. Chem., 2008, 3, 1199-1202.
83. Zmarowski, A.; Wu, H. Q.; Brooks, J. M.; Potter, M. C.; Pellicciari, R.; Schwarcz, R.; Bruno, J. P. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur. J. Neurosci., 2009, 29, 529-538.
84. Beggiato, S.; Tanganelli, S.; Fuxe, K.; Antonelli, T.; Schwarcz, R.; Ferraro, L. Endogenous kynurenic acid regulates extracellular GABA levels in the rat prefrontal cortex. Neuropharmacology, 2014, 82, 11-18.
85. Rossi, F.; Valentina, C.; Garavaglia, S.; Sathyasaikumar, K. V.; Schwarcz, R.; Kojima, S.; Okuwaki, K.; Ono, S.; Kajii, Y.; Rizzi, M. Crystal structure-based selective targeting of the pyridoxal 5'- phosphate dependent enzyme kynurenine aminotransferase II for cognitive enhancement. J. Med. Chem., 2010, 53, 5684-5689.
86. Alkondon, M.; Pereira, E. F.; Eisenberg, H. M.; Kajii, Y.; Schwarcz, R.; Albuquerque, E. X. Age dependency of inhibition of alpha7 nicotinic receptors and tonically active N-methyl-Daspartate receptors by endogenously produced kynurenic acid in the brain. J. Pharmacol. Exp. Ther., 2011, 337, 572-582.
87. Dounay, A. B.; Anderson, M.; Bechle, B. M.; Campbell, B. M.; Claffey, M. M.; Evdokimov, A.; Evrard, E.; Fonseca, K. R.; Gan, X.; Ghosh, S.; Hayward, M. M.; Horner, W.; Kim, J. Y.; McAllister, L. A.; Pandit, J.; Paradis, V.; Parikh, V. D.; Reese, M. R.; Rong, S.; Salafia, M. A.; Schuyten, K.; Strick, C. A.; Tuttle, J. B.; Valentine, J.; Wang, H.; Zawadzke, L. E.; Verhoest, P. R. Discovery of brain-penetrant, irreversible kynurenine aminotransferase ii inhibitors for schizophrenia. ACS Med. Chem. Lett., 2012, 3, 187-192.
88. Koshy Cherian, A.; Gritton, H.; Johnson, D. E.; Young, D.; Kozak, R.; Sarter, M. A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats. Neuropharmacology, 2014, 82, 41-48.
89. Tuttle, J. B.; Anderson, M.; Bechle, B. M.; Campbell, B. M.; Chang, C.; Dounay, A. B.; Evrard, E.; Fonseca, K. R.; Gan, X.; Ghosh, S.; Horner, W.; James, L. C.; Kim, J. Y.; McAllister, L. A.; Pandit, J.; Parikh, V. D.; Rago, B. J.; Salafia, M. A.; Strick, C. A.; Zawadzke, L. E.; Verhoest, P. R. Structure-based design of irreversible human KAT II inhibitors: Discovery of new potencyenhancing interactions. ACS Med. Chem. Lett., 2013, 4, 37-40.
90. Dounay, A. B.; Anderson, M.; Bechle, B. M.; Evrard, E.; Gan, X.; Kim, J.Y.; McAllister, L. A.; Pandit, J.; Rong, S.; Salafia, M. A.; Tuttle, J. B.; Zawadzke, L. E.; Verhoest, P. R. PF-04859989 as a template for structure-based drug design: Identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency. Bioorg. Med. Chem. Lett., 2013, 23, 1961- 1966.